Evidence map›Paper›PMID 42660882›Full record

ArticleNature communications2026

Anti-malaria antibody engineering broadens recognition motifs and reveals new homotypic interactions that enhance protective breadth.

Jihwan Chun, Prabhanshu Tripathi, Yevel Flores-Garcia, Bharat Madan, Gene A Lee, Ahmed S Fahad, Haotian Lei, I-Ting Teng, Nicholas K Hurlburt, Barbara J Flynn and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jihwan Chun *The Ragon Institute of Massachusetts General Brigham, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.
Prabhanshu Tripathi *Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-1282-2848
Yevel Flores-GarciaMalaria Research Institute, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Bharat MadanThe Ragon Institute of Massachusetts General Brigham, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.
Gene A LeeThe Ragon Institute of Massachusetts General Brigham, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.
Ahmed S FahadThe Ragon Institute of Massachusetts General Brigham, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.
Haotian LeiResearch Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0002-4882-0249
I-Ting TengVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Nicholas K HurlburtVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-9891-916X
Barbara J FlynnVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Marie PanceraVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-9217-6270
Kazutoyo MiuraVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-4455-2432
Tongqing ZhouVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3935-4637
Azza H IdrisThe Ragon Institute of Massachusetts General Brigham, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1847-5488
Fidel ZavalaMalaria Research Institute, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-1414-6196
Robert A SederVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3133-0849
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3560-232X
Brandon J DeKoskyThe Ragon Institute of Massachusetts General Brigham, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA. dekosky@mit.edu.ORCID http://orcid.org/0000-0001-6406-0836

Funding

Potent broadly neutralizing antibody development against the HIV-1 fusion peptide epitopeR01AI181684 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Brandon James DeKosky · 2023 to 2026
$3.0M
Comprehensive analysis of human adaptive immune receptors to elucidate correlates of Epstein-Barr virus disease suppressionDP5OD023118 · OD · UNIVERSITY OF KANSAS LAWRENCE · PI DEKOSKY, BRANDON JAMES · 2016 to 2022
$2.2M
Potent Antibody Protection Against P. falciparum and P. vivax MalariaR01AI192975 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Brandon James DeKosky · 2025 to 2026
$1.6M
NIAID NIH HHS R01 AI181684NIAID NIH HHS R01 AI192975NIH HHS DP5 OD023118U.S. Department of Health & Human Services | National Institutes of Health (NIH) DP5OD023118U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI181684U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AI192975
6 · The paper itself

Abstract

The monoclonal antibody L9 mediates high-level protection against malaria in children for up to 6 months in Africa. L9 preferentially binds with high affinity to a triplicate of NVDP-minor repeats on the P. falciparum circumsporozoite protein (PfCSP). Here, we sought to improve the affinity of L9 to enhance protection against rare strains with two spatially separated minor repeats or a single minor repeat. Site saturation mutagenesis and yeast display-screening identified a panel of affinity-improved variants. In vivo challenge showed one variant, L9_yd19, to be modestly more potent against a transgenic Plasmodium encoding chimeric CSP with two widely spaced minor repeats from a Kenyan parasite strain, with no loss in potency against the benchmark 3D7 strain with its standard complement of minor repeats. L9_yd19 also had high affinity against NANP-major repeats and was protective against transgenic Plasmodium expressing CSP with a NANP

Indexed as

Antibodies, MonoclonalAntibodies, ProtozoanMalaria, FalciparumPlasmodium falciparumProtozoan ProteinsAnimalsAntibody AffinityCryoelectron MicroscopyHumansMalaria VaccinesProtein EngineeringAntibodies, MonoclonalAntibodies, Protozoancircumsporozoite protein, ProtozoanMalaria VaccinesProtozoan Proteins

Identifiers

PMID42660882
PMCPMC13522539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.